Stock Price & Analysis

Based on the analysis of IRTC's current price trends, technical indicators, and analyst sentiment, it is recommended to hold the stock as it is currently testing support levels with mixed analyst sentiment.

The price target for IRTC stock in 2025 is $130, driven by strong revenue growth and positive analyst sentiment. Analysts have raised their price targets, citing robust FY25 guidance and accelerating ZioMCT adoption.

The S1 support level for IRTC Stock is $98.44 ,The R1 resistant level for IRTC Stock is $105.99.

As of the end of day on 2025-03-24, the price of IRTC Stock was $105.26.

The target price for IRTC Stock according to analyst rating is 130.27, with the highest price target at 152.00 and the lowest at 91.00. Analysts have a Strong Buy rating on IRTC Stock overall.

The market cap of IRTC is $3.3B.

Analysis and Insights

Technical Analysis:

IRTC's stock is currently trading at $100.345, slightly below its Fibonacci pivot of $102.38. The RSI values (6: 51.30, 12: 47.28, 14: 47.47) suggest the stock is not overbought, with the 14-day RSI indicating a potential oversold condition. The Stochastic Oscillator readings (K: 22.19, D: 18.69) also support this, as they are below 30, indicating undervaluation. The MACD is negative (-1.89), showing bearish momentum, but the MACD histogram (-1.00) suggests weakening bearish strength.

Fundamental Analysis:

IRTC has shown strong revenue growth, exceeding its FY24 guidance with record account openings and contributions from large national accounts. Analysts have raised their price targets, with Baird, Oppenheimer, and BTIG increasing targets to $133, $130, and $135 respectively, reflecting confidence in the company's growth prospects.

Analyst Sentiment:

Analysts are optimistic, with multiple firms raising their price targets. This positive sentiment, combined with strong revenue growth, suggests the stock is fairly valued, with potential for further growth.

Conclusion:

IRTC appears fairly valued given its strong fundamentals and positive analyst sentiment. While technical indicators show bearish momentum, the company's growth prospects and analyst confidence suggest it is not overvalued.

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

IRTC stock is predicted to reach approximately $180-$200 by 2030, driven by strong earnings growth and expanding market share. The company's robust financial performance and positive industry trends support this upside potential.

IRTC has a total of 2000 employees.